Warren Buffett's Successor Greg Abel Just Sold This Long-Time Berkshire Hathaway Holding

Greg Abel inherits a roughly $320 billion marketable equity portfolio and about $354 billion in cash at Berkshire Hathaway; SEC filings show the first reported transaction under his tenure was the sale of 1.7 million DaVita shares, a repurchase recorded under a preexisting agreement after DaVita bought back $200 million of stock. DaVita reported revenue up 10% and adjusted EPS up 52% year-over-year and gave 2026 guidance implying ~45% EPS growth and a 10% rise in free cash flow, while Berkshire has registered to sell virtually all of its 325,442,152 shares of Kraft Heinz amid disagreement over a proposed split (Berkshire took a $3.8 billion write-down on the holding last year). Investors will likely watch Berkshire’s mid-May 13-F for any material portfolio shifts under Abel.

Analysis

Market structure: Abel steps into control of ~$320B public equity and ~$354B cash, creating asymmetric supply risk for specific names (notably KHC) and a reallocation opportunity into buybacks/M&A elsewhere. Short-term winners: DaVita (DVA) and dialysis peers on renewed fundamental beat (DVA trading ~9.3x 2026 EPS midpoint) and potential re-rating; losers: Kraft Heinz (KHC) if Berkshire monetizes its ~325M-share registration — that supply can depress price and elevate IV. Cross-asset: expect KHC implied volatility and CDS spreads to widen; a material Berkshire rotation into buyouts/M&A could bid mid-term credit markets and push slight steepening in Treasuries if corporate deal flow rises.

Risk assessment: Tail risks include accelerated GLP-1 adoption materially reducing dialysis demand (multi-year hit to DVA), a block sale of KHC creating liquidity/market-structure squeezes, or a KHC reorg with tax/regulatory friction. Immediate window (days–weeks): headline-driven moves around earnings/repurchase notices and 13F (mid-May). Short/long-term (months–years): Abel’s allocation choices — passive hold vs active redeployment — will reprice entire BRK NAV multiple. Hidden dependency: Berkshire may prefer private M&A (uses cash off balance sheet), muting public-market supply but increasing competition for large private assets.

Trade implications: Direct plays — establish a 2–4% long position in DVA (target 15–30% upside over 6–12 months) with a 12% stop-loss; initiate a modest 1–2% short KHC (or buy 3–6 month put spreads 10–20% OTM sized to 1% portfolio risk) ahead of potential selling pressure. Pair trade — long DVA vs short KHC to isolate sector-insensitive alpha. Options — buy KHC put spreads to cap premium, and sell covered calls on initial DVA position to fund carry if IV remains elevated.

Contrarian angles: The market conflates “registration to sell” with inevitable immediate liquidation; historically Berkshire registrations often precede opportunistic, staggered sales — not block dumps — so any >10% intraday KHC move is likely overdone. DVA may be underpriced given 45% EPS guidance; if GLP-1 disruption fails to accelerate, DVA could rerate above 12x in 6–12 months. Watch mid-May 13F and KHC reorg filings as the primary catalysts that will reveal true intent and create liquid entry points.

Key Decisions for Investors

• Establish a 2–4% long position in DaVita (DVA) within the next 2–4 weeks, target 15–30% upside over 6–12 months; size with a 12% stop-loss and sell-to-open 1–2 covered call contracts per 100 shares to collect premium if IV remains elevated.
• Initiate a tactical 1%–2% short position in Kraft Heinz (KHC) via 3–6 month put spreads (buy 15% OTM, sell 5% OTM) to limit downside while positioning for potential Berkshire selling pressure; re-evaluate after BRK 13-F mid-May or if KHC files confirm split specifics.
• Execute a relative-value pair trade: long DVA (2%) vs short KHC (1%) to isolate idiosyncratic upside in healthcare vs structural downside in consumer staples; rebalance if either leg moves >15% intra-position.
• If KHC falls >10% on Berkshire-related headlines, scale buys in tranches (25% of target lot every 10% drop) with a view to convert short exposure into long if split proceeds and fundamentals justify a post-reorg thesis; conversely, accumulate BRK.B up to 1–2% if shares dip >8% on headline-driven volatility, expecting redeployment into higher-return opportunities over 12–24 months.